Glaxo zanamivir for flu prevention is possible switch candidate, firm tells analysts.
This article was originally published in The Tan Sheet
Executive Summary
GLAXO ZANAMIVIR FOR INFLUENZA PREVENTION VIEWED AS POTENTIAL SWITCH CANDIDATE, acting Head of Internal Medical Affairs Rick Fuller, MD, told securities analysts at a company R&D update in New York City May 5. Glaxo Wellcome is conducting separate trials of the inhaled neuraminidase inhibitor zanamivir for both treatment and prophylaxis of influenza.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning